OA13147A - HPV-16 and -18 L1 VLP vaccine. - Google Patents

HPV-16 and -18 L1 VLP vaccine. Download PDF

Info

Publication number: OA13147A
Authority: OA; OAPI
Prior art keywords: hpv; types; group; infection; vlp
Prior art date: 2002-12-20

Application number

OA1200500189A

Other languages

English (en)

Inventor

Gary Dubin

Bruce Innis

Moncef Mohammed Slaoui

Martine Anne Cecile Wettendorff

Original Assignee

Glaxosmithkline Biolog Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-20

Filing date

2003-12-18

Publication date

2006-12-13

2003-12-18 Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa

2006-12-13 Publication of OA13147A publication Critical patent/OA13147A/en

Links

229960005486 vaccine Drugs 0.000 title claims description 46
241000341655 Human papillomavirus type 16 Species 0.000 title claims description 15
208000015181 infectious disease Diseases 0.000 claims abstract description 53
201000010099 disease Diseases 0.000 claims abstract description 22
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 22
239000000203 mixture Substances 0.000 claims description 38
239000002671 adjuvant Substances 0.000 claims description 18
239000000902 placebo Substances 0.000 claims description 16
229940068196 placebo Drugs 0.000 claims description 16
231100000590 oncogenic Toxicity 0.000 claims description 15
230000002246 oncogenic effect Effects 0.000 claims description 15
108090000623 proteins and genes Proteins 0.000 claims description 13
102000004169 proteins and genes Human genes 0.000 claims description 13
230000028993 immune response Effects 0.000 claims description 9
230000001939 inductive effect Effects 0.000 claims description 6
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 claims description 5
229910021502 aluminium hydroxide Inorganic materials 0.000 claims description 3
230000001681 protective effect Effects 0.000 claims description 3
230000002163 immunogen Effects 0.000 claims description 2
229940024545 aluminum hydroxide Drugs 0.000 claims 1
239000012634 fragment Substances 0.000 claims 1
241000701806 Human papillomavirus Species 0.000 description 157
206010028980 Neoplasm Diseases 0.000 description 27
238000000034 method Methods 0.000 description 24
201000011510 cancer Diseases 0.000 description 21
150000007949 saponins Chemical class 0.000 description 15
229930182490 saponin Natural products 0.000 description 14
235000017709 saponins Nutrition 0.000 description 14
208000022361 Human papillomavirus infectious disease Diseases 0.000 description 12
239000002158 endotoxin Substances 0.000 description 12
229940035032 monophosphoryl lipid a Drugs 0.000 description 12
229920006008 lipopolysaccharide Polymers 0.000 description 11
235000018102 proteins Nutrition 0.000 description 11
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 9
238000009472 formulation Methods 0.000 description 8
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 7
229910052782 aluminium Inorganic materials 0.000 description 7
239000004411 aluminium Substances 0.000 description 7
208000009608 Papillomavirus Infections Diseases 0.000 description 5
239000000427 antigen Substances 0.000 description 5
102000036639 antigens Human genes 0.000 description 5
108091007433 antigens Proteins 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
235000001014 amino acid Nutrition 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
231100000252 nontoxic Toxicity 0.000 description 4
230000003000 nontoxic effect Effects 0.000 description 4
239000001397 quillaja saponaria molina bark Substances 0.000 description 4
238000002255 vaccination Methods 0.000 description 4
UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 3
210000004899 c-terminal region Anatomy 0.000 description 3
230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 3
239000002245 particle Substances 0.000 description 3
230000004044 response Effects 0.000 description 3
241000196324 Embryophyta Species 0.000 description 2
241000701828 Human papillomavirus type 11 Species 0.000 description 2
239000000232 Lipid Bilayer Substances 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
241001631646 Papillomaviridae Species 0.000 description 2
229920004890 Triton X-100 Polymers 0.000 description 2
239000013504 Triton X-100 Substances 0.000 description 2
230000003321 amplification Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
229960003964 deoxycholic acid Drugs 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000002949 hemolytic effect Effects 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
230000009826 neoplastic cell growth Effects 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
238000009595 pap smear Methods 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
230000001568 sexual effect Effects 0.000 description 2
FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
SNKAWJBJQDLSFF-NVKMUCNASA-N 1,2-dioleoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC SNKAWJBJQDLSFF-NVKMUCNASA-N 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
244000005894 Albizia lebbeck Species 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
241000606161 Chlamydia Species 0.000 description 1
239000004380 Cholic acid Substances 0.000 description 1
241000305071 Enterobacterales Species 0.000 description 1
206010018910 Haemolysis Diseases 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241000709701 Human poliovirus 1 Species 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
241001092142 Molina Species 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
241001454523 Quillaja saponaria Species 0.000 description 1
235000009001 Quillaja saponaria Nutrition 0.000 description 1
241000607149 Salmonella sp. Species 0.000 description 1
241000219287 Saponaria Species 0.000 description 1
208000019802 Sexually transmitted disease Diseases 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
101710172711 Structural protein Proteins 0.000 description 1
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
150000001399 aluminium compounds Chemical class 0.000 description 1
239000013011 aqueous formulation Substances 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
229940093761 bile salts Drugs 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
208000019065 cervical carcinoma Diseases 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
235000019416 cholic acid Nutrition 0.000 description 1
229960002471 cholic acid Drugs 0.000 description 1
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
150000002016 disaccharides Chemical group 0.000 description 1
239000003814 drug Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000006260 foam Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
230000008588 hemolysis Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
229960001438 immunostimulant agent Drugs 0.000 description 1
239000003022 immunostimulating agent Substances 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000002356 laser light scattering Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
229920002114 octoxynol-9 Polymers 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
-1 polyoxyethylene Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000000601 reactogenic effect Effects 0.000 description 1
229940045946 sodium taurodeoxycholate Drugs 0.000 description 1
239000000243 solution Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
239000012646 vaccine adjuvant Substances 0.000 description 1
229940124931 vaccine adjuvant Drugs 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Virology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Biochemistry (AREA)
Immunology (AREA)
Microbiology (AREA)
Wood Science & Technology (AREA)
Gastroenterology & Hepatology (AREA)
Biotechnology (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Mycology (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

OA1200500189A 2002-12-20 2003-12-18 HPV-16 and -18 L1 VLP vaccine. OA13147A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US43503502P	2002-12-20	2002-12-20
US49665303P	2003-08-20	2003-08-20

Publications (1)

Publication Number	Publication Date
OA13147A true OA13147A (en)	2006-12-13

Family

ID=32685362

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200500189A OA13147A (en)	2002-12-20	2003-12-18	HPV-16 and -18 L1 VLP vaccine.

Country Status (28)

Country	Link
US (2)	US20060251676A1 (pt)
EP (1)	EP1572233B1 (pt)
JP (1)	JP5475939B2 (pt)
KR (3)	KR20120118087A (pt)
AP (1)	AP2005003347A0 (pt)
AR (1)	AR042530A1 (pt)
AT (1)	ATE503492T1 (pt)
AU (1)	AU2003293942B2 (pt)
BE (3)	BE2015C068I2 (pt)
BR (1)	BR0317544A (pt)
CA (1)	CA2510457C (pt)
CY (1)	CY1111552T1 (pt)
DE (1)	DE60336581D1 (pt)
DK (1)	DK1572233T3 (pt)
EA (2)	EA200701633A1 (pt)
EC (1)	ECSP055869A (pt)
IL (1)	IL169085A (pt)
IS (1)	IS2811B (pt)
MA (1)	MA27581A1 (pt)
MX (1)	MXPA05006764A (pt)
MY (1)	MY144492A (pt)
NO (1)	NO20052846L (pt)
NZ (1)	NZ540811A (pt)
OA (1)	OA13147A (pt)
PL (1)	PL215257B1 (pt)
PT (1)	PT1572233E (pt)
TW (1)	TWI349557B (pt)
WO (1)	WO2004056389A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2284287T3 (es)	1998-10-16	2007-11-01	Glaxosmithkline Biologicals S.A.	Sistemas adyuvantes y vacunas.
GB0206360D0 (en)	2002-03-18	2002-05-01	Glaxosmithkline Biolog Sa	Viral antigens
US7858098B2 (en)	2002-12-20	2010-12-28	Glaxosmithkline Biologicals, S.A.	Vaccine
US7758866B2 (en)	2004-06-16	2010-07-20	Glaxosmithkline Biologicals, S.A.	Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
KR20070029254A (ko) *	2004-06-16	2007-03-13	글락소스미스클라인 바이오로지칼즈 에스.에이.	Ｈｐｖ 16과 ｈｐｖ 18 및 적어도 ｈｐｖ 31, 45 또는52로부터 선택된 또 다른 ｈｐｖ 유형에 대한 백신
WO2006113209A1 (en)	2005-04-15	2006-10-26	The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
AR054259A1 (es) *	2005-04-26	2007-06-13	Glaxosmithkline Biolog Sa	Vacuna contra virus de papiloma humano (hpv)
MX2007013475A (es) *	2005-04-26	2008-04-02	Glaxosmithkline Biolog Sa	Vacuna.
EP2154147B1 (en) *	2007-04-29	2015-10-07	Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.	A truncated l1 protein of human papillomavirus 16
EP2147926B1 (en)	2007-04-29	2016-08-24	Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.	Truncated human papillomavirus type 18 l1 proteins
WO2010099580A1 (en) *	2009-03-05	2010-09-10	Jenny Colleen Mccloskey	Treatment of infection
US9566323B2 (en) *	2009-06-19	2017-02-14	Eyegene Inc.	Vaccine for cervical cancer
US20170212116A1 (en)	2014-01-31	2017-07-27	Ulisse Biomed Srl	Biosensors for the detection of infection and associated maladies
CA2965498A1 (en)	2014-10-24	2016-04-28	Hpvvax, Llc.	Compositions and uses of a papilloma virus (hpv) vaccine for the treatment of hpv related cancer and skin lesions
US10799574B2 (en)	2014-10-24	2020-10-13	Hpvvax. Llc	Method and composition for treating cancer or skin lesion using a vaccine
CA2987864C (en) *	2015-06-02	2020-08-18	Terumo Kabushiki Kaisha	Adjuvant composition containing aluminum and vaccine composition containing the same
CN122399006A (zh)	2016-02-27	2026-07-17	哈普威克斯有限责任公司	使用疫苗治疗癌症或皮肤病变的方法和组合物
SG11202008539YA (en) *	2018-03-06	2020-10-29	Precigen Inc	Human papillomavirus vaccines and uses of the same
IL277128B2 (en)	2018-03-06	2025-11-01	Precigen Inc	Hepatitis b vaccines and uses of the same
BR112020024699A2 (pt) *	2018-06-04	2021-03-09	Xiamen University	Mutante da proteína l1 do papilomavírus humano tipo 18
CA3121247A1 (en)	2018-12-03	2020-06-11	Board Of Regents, The University Of Texas System	Oligo-benzamide analogs and their use in cancer treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4332596A1 (de) *	1993-09-24	1995-03-30	Martin Josef Dr Sapp	Monoklonale Antikörper
AU742409B2 (en)	1997-09-05	2002-01-03	Medimmune, Llc	In vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPs)
ATE413188T1 (de) *	1999-02-05	2008-11-15	Merck & Co Inc	Menschliche papillomavirus impfstoff- formulierungen
US6245568B1 (en)	1999-03-26	2001-06-12	Merck & Co., Inc.	Human papilloma virus vaccine with disassembled and reassembled virus-like particles
GB9921146D0 (en) *	1999-09-07	1999-11-10	Smithkline Beecham Biolog	Novel composition
US6908613B2 (en) *	2000-06-21	2005-06-21	Medimmune, Inc.	Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
KR100919266B1 (ko) *	2000-06-26	2009-09-30	엔벤타 바이오파마슈티컬스 코포레이션	인간 파필로마 바이러스 치료법

2003
- 2003-12-18 PT PT03789346T patent/PT1572233E/pt unknown
- 2003-12-18 EA EA200701633A patent/EA200701633A1/ru unknown
- 2003-12-18 EP EP03789346A patent/EP1572233B1/en not_active Expired - Lifetime
- 2003-12-18 TW TW092135963A patent/TWI349557B/zh not_active IP Right Cessation
- 2003-12-18 DK DK03789346.8T patent/DK1572233T3/da active
- 2003-12-18 CA CA2510457A patent/CA2510457C/en not_active Expired - Lifetime
- 2003-12-18 NZ NZ540811A patent/NZ540811A/en not_active IP Right Cessation
- 2003-12-18 KR KR1020127026719A patent/KR20120118087A/ko not_active Withdrawn
- 2003-12-18 JP JP2005502554A patent/JP5475939B2/ja not_active Expired - Lifetime
- 2003-12-18 KR KR1020127027784A patent/KR101361769B1/ko not_active Expired - Lifetime
- 2003-12-18 US US10/540,099 patent/US20060251676A1/en not_active Abandoned
- 2003-12-18 MY MYPI20034868A patent/MY144492A/en unknown
- 2003-12-18 WO PCT/EP2003/014562 patent/WO2004056389A1/en not_active Ceased
- 2003-12-18 AT AT03789346T patent/ATE503492T1/de active
- 2003-12-18 DE DE60336581T patent/DE60336581D1/de not_active Expired - Lifetime
- 2003-12-18 BR BR0317544-8A patent/BR0317544A/pt not_active Application Discontinuation
- 2003-12-18 PL PL377710A patent/PL215257B1/pl unknown
- 2003-12-18 OA OA1200500189A patent/OA13147A/en unknown
- 2003-12-18 AU AU2003293942A patent/AU2003293942B2/en not_active Expired
- 2003-12-18 AP AP2005003347A patent/AP2005003347A0/xx unknown
- 2003-12-18 KR KR1020057011497A patent/KR20050086924A/ko not_active Ceased
- 2003-12-18 MX MXPA05006764A patent/MXPA05006764A/es active IP Right Grant
- 2003-12-18 AR ARP030104709A patent/AR042530A1/es unknown
- 2003-12-18 EA EA200500834A patent/EA009179B1/ru not_active IP Right Cessation
2005
- 2005-04-26 US US11/114,301 patent/US20050287161A1/en not_active Abandoned
- 2005-06-09 IL IL169085A patent/IL169085A/en active IP Right Grant
- 2005-06-09 IS IS7885A patent/IS2811B/is unknown
- 2005-06-13 NO NO20052846A patent/NO20052846L/no not_active Application Discontinuation
- 2005-06-20 EC EC2005005869A patent/ECSP055869A/es unknown
- 2005-07-18 MA MA28398A patent/MA27581A1/fr unknown
2011
- 2011-06-08 CY CY20111100549T patent/CY1111552T1/el unknown
2015
- 2015-12-09 BE BE2015C068C patent/BE2015C068I2/fr unknown
- 2015-12-09 BE BE2015C069C patent/BE2015C069I2/fr unknown
- 2015-12-09 BE BE2015C067C patent/BE2015C067I2/fr unknown

Also Published As

Publication number	Publication date
MA27581A1 (fr)	2005-10-03
TW200423957A (en)	2004-11-16
BE2015C068I2 (pt)	2024-08-08
AR042530A1 (es)	2005-06-22
NZ540811A (en)	2007-03-30
IL169085A (en)	2014-04-30
DK1572233T3 (da)	2011-06-27
EA200500834A1 (ru)	2006-02-24
EA009179B1 (ru)	2007-12-28
IL169085A0 (en)	2007-07-04
JP5475939B2 (ja)	2014-04-16
BE2015C067I2 (pt)	2024-08-08
ATE503492T1 (de)	2011-04-15
TWI349557B (en)	2011-10-01
IS7885A (is)	2005-06-09
AP2005003347A0 (en)	2005-06-30
KR20120118087A (ko)	2012-10-25
ECSP055869A (es)	2005-09-20
PL377710A1 (pl)	2006-02-06
DE60336581D1 (de)	2011-05-12
CA2510457A1 (en)	2004-07-08
US20050287161A1 (en)	2005-12-29
EA200701633A1 (ru)	2007-12-28
NO20052846L (no)	2005-07-13
EP1572233B1 (en)	2011-03-30
US20060251676A1 (en)	2006-11-09
CA2510457C (en)	2011-12-06
WO2004056389A1 (en)	2004-07-08
EP1572233A1 (en)	2005-09-14
HK1085378A1 (en)	2006-08-25
MY144492A (en)	2011-09-30
JP2006512413A (ja)	2006-04-13
MXPA05006764A (es)	2005-09-08
IS2811B (is)	2012-11-15
BE2015C069I2 (pt)	2024-08-08
PT1572233E (pt)	2011-06-07
AU2003293942A1 (en)	2004-07-14
AU2003293942B2 (en)	2009-12-10
BR0317544A (pt)	2005-11-22
KR20120123616A (ko)	2012-11-08
KR101361769B1 (ko)	2014-02-10
CY1111552T1 (el)	2015-08-05
PL215257B1 (pl)	2013-11-29
KR20050086924A (ko)	2005-08-30

Publication	Publication Date	Title
CA2510457C (en)	2011-12-06	Hpv-16 and -18 l1 vlp vaccine
AU2002310802B2 (en)	2005-03-24	Multivalent vaccine comprising an HIV antigen and an HSV antigen and/or an HPV antigen
AU2002310802A1 (en)	2003-04-17	Multivalent vaccine comprising an HIV antigen and an HSV antigen and/or an HPV antigen
JP2012102132A (ja)	2012-05-31	Ｈｐｖ１６およびｈｐｖ１８ならびにｈｐｖ３１、４５または５２から選ばれる少なくとも１つの別のｈｐｖ型に対するワクチン
CN100418577C (zh)	2008-09-17	Hpv-16和hpv-18l1vlp疫苗
KR20080005585A (ko)	2008-01-14	백신
MXPA06014515A (es)	2007-03-23	Vacuna contra vph16 y vph18 y al menos otro tipo de vph seleccionado de vph 31, 45 o 52.
US7858098B2 (en)	2010-12-28	Vaccine
ES2361913T3 (es)	2011-06-24	Uso de hpv16 y hpv18 como vacunas con uno o más oncógenos de los tipos 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68.
HK1085378B (en)	2011-08-26	Use of hpv16 and hpv18 as vaccine against one or more of oncogenic hpv type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
CN101217975A (zh)	2008-07-09	疫苗
AU2006239471A1 (en)	2006-11-02	Vaccine